401 related articles for article (PubMed ID: 12118339)
41. Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma.
Lindforss U; Fredholm H; Papadogiannakis N; Gad A; Zetterquist H; Olivecrona H
Cancer; 2000 Jun; 88(12):2661-7. PubMed ID: 10870047
[TBL] [Abstract][Full Text] [Related]
42. Prospective assessment of allelic losses at 4p14-16 in colorectal cancer: two mutational patterns and a locus associated with poorer survival.
Arribas R; Ribas M; Risques RA; Masramon L; Tórtola S; Marcuello E; Aiza G; Miró R; Capellà G; Peinado MA
Clin Cancer Res; 1999 Nov; 5(11):3454-9. PubMed ID: 10589758
[TBL] [Abstract][Full Text] [Related]
43. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas.
Komuro H; Hayashi Y; Kawamura M; Hayashi K; Kaneko Y; Kamoshita S; Hanada R; Yamamoto K; Hongo T; Yamada M
Cancer Res; 1993 Nov; 53(21):5284-8. PubMed ID: 8221663
[TBL] [Abstract][Full Text] [Related]
44. Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer.
Friedrich MG; Erbersdobler A; Schwaibold H; Conrad S; Huland E; Huland H
J Urol; 2000 Mar; 163(3):1039-42. PubMed ID: 10688045
[TBL] [Abstract][Full Text] [Related]
45. p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang.
Buller RE; Shahin MS; Holmes RW; Hatterman M; Kirby PA; Sood AK
Am J Obstet Gynecol; 2001 Apr; 184(5):891-902; discussion 902-3. PubMed ID: 11303196
[TBL] [Abstract][Full Text] [Related]
46. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
47. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
Thorlacius S; Börresen AL; Eyfjörd JE
Cancer Res; 1993 Apr; 53(7):1637-41. PubMed ID: 8453635
[TBL] [Abstract][Full Text] [Related]
48. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers.
Hartmann A; Blaszyk H; McGovern RM; Schroeder JJ; Cunningham J; De Vries EM; Kovach JS; Sommer SS
Oncogene; 1995 Feb; 10(4):681-8. PubMed ID: 7862445
[TBL] [Abstract][Full Text] [Related]
49. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
50. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.
Kastrinakis WV; Ramchurren N; Rieger KM; Hess DT; Loda M; Steele G; Summerhayes IC
Oncogene; 1995 Aug; 11(4):647-52. PubMed ID: 7651727
[TBL] [Abstract][Full Text] [Related]
51. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis.
Saitoh S; Cunningham J; De Vries EM; McGovern RM; Schroeder JJ; Hartmann A; Blaszyk H; Wold LE; Schaid D; Sommer SS
Oncogene; 1994 Oct; 9(10):2869-75. PubMed ID: 8084591
[TBL] [Abstract][Full Text] [Related]
52. p53 mutations in lung cancer following radiation therapy for Hodgkin's disease.
De Benedetti VM; Travis LB; Welsh JA; van Leeuwen FE; Stovall M; Clarke EA; Boice JD; Bennett WP
Cancer Epidemiol Biomarkers Prev; 1996 Feb; 5(2):93-8. PubMed ID: 8850268
[TBL] [Abstract][Full Text] [Related]
53. Usefulness of analysis of p53 alteration and observation of surface microstructure for diagnosis of ulcerative colitis-associated colorectal neoplasia.
Fujii S; Fujimori T; Chiba T
J Exp Clin Cancer Res; 2003 Mar; 22(1):107-15. PubMed ID: 12725330
[TBL] [Abstract][Full Text] [Related]
54. Loss of heterozygosity and p53 gene mutations in breast cancer.
Deng G; Chen LC; Schott DR; Thor A; Bhargava V; Ljung BM; Chew K; Smith HS
Cancer Res; 1994 Jan; 54(2):499-505. PubMed ID: 8275488
[TBL] [Abstract][Full Text] [Related]
55. No difference in the occurrence of mismatch repair defects and APC and CTNNB1 genes mutation in a multi-racial colorectal carcinoma patient cohort.
Tan LP; Ng BK; Balraj P; Lim PK; Peh SC
Pathology; 2007 Apr; 39(2):228-34. PubMed ID: 17454753
[TBL] [Abstract][Full Text] [Related]
56. Genotyping of p53 codon 175 in colorectal cancer.
Krajewska WM; Stawińska M; Bryś M; Młynarski W; Witas HW; Okruszek A; Kiliańska ZM
Med Sci Monit; 2003 May; 9(5):BR188-91. PubMed ID: 12761448
[TBL] [Abstract][Full Text] [Related]
57. APC gene loss of heterozygosity, mutations, E1317Q, and I1307K germ-line variants in sporadic colon cancer in Croatia.
Kapitanović S; Cacev T; Radosević S; Spaventi S; Spaventi R; Pavelić K
Exp Mol Pathol; 2004 Dec; 77(3):193-200. PubMed ID: 15507235
[TBL] [Abstract][Full Text] [Related]
58. p53 gene mutations in medulloblastoma. Immunohistochemistry, gel shift analysis, and sequencing.
Badiali M; Iolascon A; Loda M; Scheithauer BW; Basso G; Trentini GP; Giangaspero F
Diagn Mol Pathol; 1993 Mar; 2(1):23-8. PubMed ID: 8287222
[TBL] [Abstract][Full Text] [Related]
59. Expression of p53 and 17p allelic loss in colorectal carcinoma.
Cunningham J; Lust JA; Schaid DJ; Bren GD; Carpenter HA; Rizza E; Kovach JS; Thibodeau SN
Cancer Res; 1992 Apr; 52(7):1974-80. PubMed ID: 1551126
[TBL] [Abstract][Full Text] [Related]
60. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer.
Massenkeil G; Oberhuber H; Hailemariam S; Sulser T; Diener PA; Bannwart F; Schäfer R; Schwarte-Waldhoff I
Anticancer Res; 1994; 14(6B):2785-90. PubMed ID: 7872719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
